NeoGenomics has unveiled its new comprehensive lung solution and COMPASS Hematopathology Services portfolio. The demonstration for both products will occur at the upcoming American Society of Clinical Oncology conference to be held between May 31 and June 4.
NeoGenomics' new comprehensive lung offering is designed for complementary tissue and liquid biopsy testing, providing precise diagnosis, therapy selection, and clinical trial options. COMPASS is a portfolio of sample diagnostics services for hematological malignancies, including over 100 subtypes of leukemias, lymphomas, and myelomas. It provides an all-in-one assessment with actionable diagnostic and prognostic information tailored to patients’ needs. These offerings enable appropriate test selection for precise patient care in light of increasing FDA-approved targeted therapies and immunotherapies.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.